AKRO News and Press, Akero Therapeutics Inc. From 06/16/22

Gainers: Electric Last Mile Solutions (ELMS) +195%. Advent Technologies Holdings (ADN) +185%. Sidus Space (SIDU) +60%. Pennsylvania Real Estate Investment (PEI) +39%. Vivakor (VIVK) +32%. Akero (AKRO) +24%. Revlon (REV) +23%. Zhong Yang Financial Group (TOP) +22%. Decisionpoint Systems (DPSI)...

Gainers: Bone Biologics (BBLG) +13%. Akero Therapeutics AKRO +10%. Biotricity (BTCY) +9%. Jasper Therapeutics (JSPR) +7%. Burning Rock Biotech (BNR) +6%. Losers: AC Immune ACIU -17%. Arcellx ACLX -17%. SOPHiA GENETICS (SOPH) -16%. AirSculpt Te...

Clinical-stage biotech Akero Therapeutics (NASDAQ:AKRO) announced on Thursday that Pfizer (PFE) is set to make $25M equity investment in the company following an agreement to purchase ~2.5M of its shares at $9.90 apiece. The offering is set to close on or around June 17 and following the tran...

$25 Million Equity Investment by Pfizer at $9.90 Per Share Term Loan Facility from Hercules Providing Up to $100 Million If Fully Drawn, Akero Cash Runway Extended One Full Year From Previously Announced Q3 2023 to Q3 2024 SOUTH SAN FRANCISCO, Calif., June 16, ...

SOUTH SAN FRANCISCO, Calif., June 13, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that it will...

The following slide deck was published by Akero Therapeutics, Inc. in conjunction with this event. For further details see: Akero Therapeutics (AKRO) Investor Presentation - Slideshow

SOUTH SAN FRANCISCO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management w...

Akero Therapeutics press release (NASDAQ:AKRO): Q1 GAAP EPS of -$0.74 beats by $0.07. Cash, cash equivalents and short-term marketable securities for the period ended March 31, 2022 were $165.4 million. For further details see: Akero Therapeutics GAAP EPS of -$0.74 beats by $0.07

SOUTH SAN FRANCISCO, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported first quarter finan...

SOUTH SAN FRANCISCO, May 02, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will parti...